Roche Broadens Cervical Cancer Testing Lineup With MTM Acquisition
Roche will seek PMA approval for MTM Laboratories’ cervical cancer tests following acquisition of the diagnostics firm for up to $270 million in a deal announced July 19.
Roche will seek PMA approval for MTM Laboratories’ cervical cancer tests following acquisition of the diagnostics firm for up to $270 million in a deal announced July 19.